Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet
Portfolio Pulse from
Wall Street analysts have set an average price target for ImmunityBio (IBRX) that suggests a potential upside of 184.4%. Despite some skepticism about the reliability of price targets, positive earnings estimate revisions could indicate a favorable trend for the stock.
November 19, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio (IBRX) has been given an average price target by analysts indicating a potential 184.4% upside. Positive earnings estimate revisions may support this outlook.
The article highlights a significant potential upside for IBRX based on analyst price targets, which is a strong positive signal. Additionally, the positive trend in earnings estimate revisions further supports the potential for stock price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100